Literature DB >> 29327594

Liver Resection and Surgical Strategies for Management of Primary Liver Cancer.

Sonia T Orcutt1, Daniel A Anaya2.   

Abstract

Primary liver cancer-including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)-incidence is increasing and is an important source of cancer-related mortality worldwide. Management of these cancers, even when localized, is challenging due to the association with underlying liver disease and the complex anatomy of the liver. Although for ICC, surgical resection provides the only potential cure, for HCC, the risks and benefits of the multiple curative intent options must be considered to individualize treatment based upon tumor factors, baseline liver function, and the functional status of the patient. The principles of surgical resection for both HCC and ICC include margin-negative resections with preservation of adequate function of the residual liver. As the safety of surgical resection has improved in recent years, the role of liver resection for HCC has expanded to include selected patients with preserved liver function and small tumors (ablation as an alternative), tumors within Milan criteria (transplant as an alternative), and patients with large (>5 cm) and giant (>10 cm) HCC or with poor prognostic features (for whom surgery is infrequently offered) due to a survival benefit with resection for selected patients. An important surgical consideration specifically for ICC includes the high risk of nodal metastasis, for which portal lymphadenectomy is recommended at the time of hepatectomy for staging. For both diseases, onco-surgical strategies including portal vein embolization and parenchymal-sparing resections have increased the number of patients eligible for curative liver resection by improving patient outcomes. Multidisciplinary evaluation is critical in the management of patients with primary liver cancer to provide and coordinate the best treatments possible for these patients.

Entities:  

Keywords:  hepatectomy; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; liver neoplasms

Mesh:

Year:  2018        PMID: 29327594      PMCID: PMC5933574          DOI: 10.1177/1073274817744621

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  120 in total

1.  Total and segmental liver volume variations: implications for liver surgery.

Authors:  Eddie K Abdalla; Alban Denys; Patrick Chevalier; Rabih A Nemr; Jean-Nicolas Vauthey
Journal:  Surgery       Date:  2004-04       Impact factor: 3.982

Review 2.  Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials.

Authors:  Xingshun Qi; Yulong Tang; Dan An; Ming Bai; Xiaolei Shi; Juan Wang; Guohong Han; Daiming Fan
Journal:  J Clin Gastroenterol       Date:  2014 May-Jun       Impact factor: 3.062

3.  Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument.

Authors:  Pascal Gavriilidis; Keith J Roberts; Alan Askari; Robert P Sutcliffe; Teh-la Huo; Po-Hong Liu; Ernest Hidalgo; Philippe Compagnon; Chetana Lim; Daniel Azoulay
Journal:  J Hepatol       Date:  2017-07-08       Impact factor: 25.083

4.  Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.

Authors:  Kheng Choon Lim; Vivian W Wang; Fahad J Siddiqui; Luming Shi; Edwin S Y Chan; Hong Choon Oh; Say Beng Tan; Pierce K H Chow
Journal:  Hepatology       Date:  2014-05-29       Impact factor: 17.425

Review 5.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

Review 6.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

Review 7.  The surgical approach to HCC: our progress and results in Japan.

Authors:  Masatoshi Makuuchi; Keiji Sano
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

8.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

9.  Capecitabine Extends Survival for Biliary Tract Cancer.

Authors: 
Journal:  Cancer Discov       Date:  2017-06-01       Impact factor: 39.397

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  54 in total

1.  Clinical and prognostic value of CT perfusion imaging parameters in patients with primary liver cancer after therapy.

Authors:  Yiming Li; Yuzhou Li; Yuan Sui; Guangyao Lin; Wenqi Huang; Yinshi Zheng
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study.

Authors:  Kei Shibuya; Hiroyuki Katoh; Yoshinori Koyama; Shintaro Shiba; Masahiko Okamoto; Shohei Okazaki; Kenichiro Araki; Satoru Kakizaki; Ken Shirabe; Tatsuya Ohno
Journal:  Liver Cancer       Date:  2021-12-17       Impact factor: 11.740

3.  Comparison of portal and capsular microscopic vascular invasion in the outcomes of early HCC after curative resection.

Authors:  Ding-Sen Huang; Ting-Ting Liu; Wei-Ting Lu; Chih-Chi Wang; Chih-Che Lin; Chee-Chen Yong; Kuang-Den Chen; Yueh-Wei Liu; Yuan-Hung Kuo; Yi-Hao Yen; Tsung-Hui Hu; Ming-Chao Tsai
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

4.  Scinderin suppresses cell proliferation and predicts the poor prognosis of hepatocellular carcinoma.

Authors:  Bin Zhou; Tian-Wei Chen; Ya-Bo Jiang; Xu-Biao Wei; Chong-De Lu; Jing-Jing Li; Dong Xie; Shu-Qun Cheng
Journal:  Oncol Lett       Date:  2020-01-08       Impact factor: 2.967

5.  Propofol activates AMPK to inhibit the growth of HepG2 cells in vitro and hepatocarcinogenesis in xenograft mouse tumor models by inducing autophagy.

Authors:  Yixiong Wang; Baozhu Xu; Jianying Zhou; Xianyan Wu
Journal:  J Gastrointest Oncol       Date:  2020-12

6.  Orthotopic liver transplantation improves postoperative quality of life, survival rate and reduces recurrence rate in patients with liver cancer.

Authors:  Xia Zhang; Lizhi Lv; Zhixian Wu; Dongliang Li; Kun Zhang; Yonghai Peng
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

7.  Influence of cytokines, circulating markers and growth factors on liver regeneration and post-hepatectomy liver failure: a systematic review and meta-analysis.

Authors:  Anastasia Murtha-Lemekhova; Juri Fuchs; Omid Ghamarnejad; Mohammedsadegh Nikdad; Pascal Probst; Katrin Hoffmann
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

8.  Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities.

Authors:  Cyrill Wehling; Michael T Dill; Alexander Olkus; Christoph Springfeld; De-Hua Chang; Patrick Naumann; Thomas Longerich; Clemens Kratochwil; Arianeb Mehrabi; Uta Merle; Jan Pfeiffenberger; Christian Rupp; Karl Heinz Weiss; Markus Mieth
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-04       Impact factor: 4.553

Review 9.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

10.  High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma.

Authors:  Min Deng; Shaohua Li; Jie Mei; Wenping Lin; Jingwen Zou; Wei Wei; Rongping Guo
Journal:  Genes (Basel)       Date:  2021-06-07       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.